Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations.

OBJECTIVE The hematopoietic growth factor receptor, Fms-like tyrosine kinase-3 (Flt3), modulates survival and proliferation of myeloid and B-cell precursors. Activating mutations of Flt3 are the most common molecular abnormalities in acute myeloid leukemia (AML) and have an apparent role in leukemogenesis. However, signaling pathways mediating Flt3 effects are incompletely understood. The role of Src kinases is unknown, although some, such as Lyn, have also been linked to leukemogenesis. This study examines the role of Src kinases in Flt3 signaling and the oncogenic effects of leukemia-associated Flt3 mutations. MATERIALS AND METHODS We examined the activation and functional roles of Src kinases in human leukemic myeloid cell lines expressing wild-type Flt3 or a constitutively active mutant, and in cells stably transduced with human wild-type or mutant Flt3. RESULTS Flt3 ligand stimulation of wild-type Flt3 increased phosphorylation of Src kinase Lyn. Constitutive Lyn phosphorylation and activation was found in cells expressing constitutively active Flt3 mutants. Src kinases are implicated in downregulation of closely related receptors, but Src inhibitors had no effect on ligand-stimulated Flt3 degradation, or on the rapid degradation of an Flt3 mutant. However, growth-factor-independent proliferation resulting from mutant Flt3 expression did depend on the activity of Src kinases. CONCLUSION Our studies reveal for the first time the involvement of Src kinases in Flt3 signaling, with activation of Lyn by constitutively active Flt3 mutants as well as ligand-stimulated wild-type receptor, and show that Src kinase inhibitors block proliferative effects of Flt3 mutants found in AML. Thus, Src kinases may represent targets for inhibitor therapy in Flt3-related AML.

[1]  J. Hanke,et al.  Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor , 1996, The Journal of Biological Chemistry.

[2]  I. Lemischka,et al.  Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells , 1993, Molecular and cellular biology.

[3]  T. Naoe,et al.  Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines , 2000, Oncogene.

[4]  J. Radich,et al.  The role of FLT3 in haematopoietic malignancies , 2003, Nature Reviews Cancer.

[5]  A. Kraker,et al.  Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth , 1999, Leukemia.

[6]  S. Burakoff,et al.  Involvement of Proteasomes in Regulating Jak-STAT Pathways upon Interleukin-2 Stimulation* , 1997, The Journal of Biological Chemistry.

[7]  C. Deberry,et al.  Lyn Associates with the Juxtamembrane Region of c-Kit and Is Activated by Stem Cell Factor in Hematopoietic Cell Lines and Normal Progenitor Cells* , 1997, The Journal of Biological Chemistry.

[8]  Monilola A. Olayioye,et al.  ErbB Receptor-induced Activation of Stat Transcription Factors Is Mediated by Src Tyrosine Kinases* , 1999, The Journal of Biological Chemistry.

[9]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[10]  P. Besmer,et al.  Kit signaling through PI 3‐kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation , 1998, The EMBO journal.

[11]  S. Rane,et al.  JAKs, STATs and Src kinases in hematopoiesis , 2002, Oncogene.

[12]  T. Ley,et al.  PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. DeFranco,et al.  Positive and negative roles of the tyrosine kinase Lyn in B cell function. , 1998, Seminars in immunology.

[14]  S. Corey,et al.  Signaling via Src family kinases is required for normal internalization of the receptor c-Kit. , 1999, Blood.

[15]  J. Reilly.  FLT3 and its Role in the Pathogenesis of Acute Myeloid Leukaemia , 2003, Leukemia & lymphoma.

[16]  D. Metcalfe,et al.  Lyn is required for normal stem cell factor-induced proliferation and chemotaxis of primary hematopoietic cells. , 2001, Blood.

[17]  M. Levis,et al.  FLT3: ITDoes matter in leukemia , 2003, Leukemia.

[18]  John Calvin Reed,et al.  Interleukin-3 regulates the activity of the LYN protein-tyrosine kinase in myeloid-committed leukemic cell lines. , 1992, Blood.

[19]  D. Gilliland,et al.  FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. , 2002, Blood.

[20]  S. Armstrong,et al.  FLT3 mutations in childhood acute lymphoblastic leukemia. , 2004, Blood.

[21]  R. Mohammad,et al.  Bryostatin 1 (bryo1)-induced monocytic differentiation in THP-1 human leukemia cells is associated with enhanced c-fyn tyrosine kinase and M-CSF receptors. , 1997, Leukemia research.

[22]  K. Cornetta,et al.  Antileukemic activity of Flt3 ligand in murine leukemia. , 2000, Cancer research.

[23]  S. Corey,et al.  Src-related protein tyrosine kinases in hematopoiesis. , 1999, Blood.

[24]  M. Meyerson,et al.  Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. , 2004, Blood.

[25]  H. Saito,et al.  Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product , 1998, Leukemia.

[26]  H. Heslop,et al.  Adoptive Immunotherapy for EBV-associated Malignancies , 2005, Leukemia & lymphoma.

[27]  C. Miething,et al.  Analysing c-kit internalization using a functional c-kit-EGFP chimera containing the fluorochrome within the extracellular domain , 2002, Oncogene.

[28]  M. Ratajczak,et al.  STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[29]  T. Bird,et al.  Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene. , 1993, Oncogene.

[30]  H. Mckenna.  Role of hematopoietic growth factors/flt3 ligand in expansion and regulation of dendritic cells , 2001, Current opinion in hematology.

[31]  T. Pawson,et al.  Substrate specificities and identification of a putative binding site for PI3K in the carboxy tail of the murine Flt3 receptor tyrosine kinase. , 1994, Oncogene.

[32]  S. Lyman,et al.  c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. , 1998, Blood.

[33]  Y. Ikuno,et al.  Src Family Kinases Negatively Regulate Platelet-derived Growth Factor α Receptor-dependent Signaling and Disease Progression* , 2000, The Journal of Biological Chemistry.

[34]  B. Avalos,et al.  Deletion of a critical internalization domain in the G-CSFR in acute myelogenous leukemia preceded by severe congenital neutropenia. , 1999, Blood.

[35]  Matthew B. Wilson,et al.  Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr–Abl signal transduction and oncogenesis , 2002, Oncogene.

[36]  N. Donato,et al.  BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. , 2003, Blood.

[37]  H. Broxmeyer,et al.  p85 subunit of PI3 kinase does not bind to human Flt3 receptor, but associates with SHP2, SHIP, and a tyrosine-phosphorylated 100-kDa protein in Flt3 ligand-stimulated hematopoietic cells. , 1999, Biochemical and biophysical research communications.

[38]  T. Naoe,et al.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. , 2001, Blood.

[39]  S. Hashino,et al.  In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice. , 2001, Blood.

[40]  J. Griffin,et al.  The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.

[41]  K.,et al.  Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells , 2000, British journal of haematology.

[42]  B. Smith,et al.  A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. , 2001, Blood.

[43]  H. Drexler,et al.  FLT3 mutations in acute myeloid leukemia cell lines , 2003, Leukemia.

[44]  D. Linch,et al.  Flt3 mutations and leukaemia , 2003, British journal of haematology.

[45]  I. Touw,et al.  Defective Internalization and Sustained Activation of Truncated Granulocyte Colony-Stimulating Factor Receptor Found in Severe Congenital Neutropenia/Acute Myeloid Leukemia , 1999 .

[46]  H. Kaneko,et al.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.

[47]  W. Berdel,et al.  Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. , 2000, Blood.